Key facts
- Scientists are racing to develop a new Ebola vaccine.
- The Oxford group is using the ChADOx1 viral-vector platform.
- The ChADOx1 platform was also used for the Oxford-AstraZeneca COVID-19 vaccine.
Two scientific groups are currently engaged in a race to develop a new vaccine for Ebola. One of these efforts is being led by a team at Oxford University. They are employing the ChADOx1 viral-vector platform, a technology that previously served as the basis for the widely recognized Oxford-AstraZeneca COVID-19 vaccine. This approach leverages existing vaccine technology to accelerate the development of a new defense against the Ebola virus.